Our findings of GBPs as dual regulators of MCL-1 and BAK via two different molecular mechanisms involving protein–protein interaction and transcriptional regulation, which allow synergistic amplification of apoptotic BAK activity, accentuate GBPs as new and attractive target molecules for leukemia therapeutics and perhaps for the treatment of other types of cancers. This evidence concerns the gene MCL1 and leukemia.